The drugmaker presented Phase I data for the CD38xBCMAxCD3-directed trispecific at the International Myeloma Society meeting in Glasgow, Scotland.
The drugmaker presented Phase I data for the CD38xBCMAxCD3-directed trispecific at the International Myeloma Society meeting in Glasgow, Scotland.